CordenPharma extends oligonucleotides in Colorado

by Rick Mullin
May 13, 2018 | APPEARED IN VOLUME 96, ISSUE 20

Credit: CordenPharma
A view inside CordenPharma's expanded facility.

CordenPharma has expanded oligonucleotide active pharmaceutical ingredient manufacturing capacity at its Boulder, Colo., plant. The German company, which purchased the site from Roche in 2011, says the facility now can synthesize up to 500 kg of oligonucleotides per year, making it one of the world’s largest oligonucleotide manufacturing sites.


This article has been sent to the following recipient:

Leave A Comment

*Required to comment